eNeura Therapeutics, hard on the heels of an FDA nod for its migraine technology, brought in $2.2 million from an equity offering.
The medtech maker list a lone unnamed investor in late Dec., according to a regulatory filing.
Sunnyvale, Calif.-based eNeura won FDA clearance for its Cerena transcranial magnetic stimulator, through the agency’s less-stringent de novo premarket review pathway in Dec.
The Cerena TMS device is designed to use magnetic energy to help relieve pain associated with migraines, stimulating the occipital cortex in the brain via a prescription device that patients hold against the back of the head after the onset of pain.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!